Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The FDA granted accelerated approval to Bristol Myers Squibb's Krazati (adagrasib) with cetuximab for adult patients with K...
CORRECTION : JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $...
JP Morgan analyst Tycho Peterson maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54.
QIAGEN announces a comprehensive growth strategy by 2028. The plan includes significant shareholder returns, new product launch...
Reuters reports.
QIAGEN's leadership team will present the new 2028 targets, highlighting vision and strategy to sharpen its focus on growth...
The company expects to deliver solid profitable growth through 2028 – led by about 7% compound annual sales growth (CAGR) at co...
